Twist Bioscience Launches Monkeypox Virus Synthetic DNA Controls
July 14 2022 - 7:00AM
Business Wire
New synthetic controls add to growing portfolio
of NGS applications for viral diseases
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling
customers to succeed through its offering of high-quality synthetic
DNA using its silicon platform, today launched two human monkeypox
virus synthetic DNA controls1.
Positive controls provide quality control measures for the
development, verification, and ongoing validation of both
next-generation sequencing (NGS) and polymerase chain reaction
(PCR) assays. The Twist synthetic DNA controls include both known
clades of the monkeypox virus, currently named the Congo Basin
(Central African) clade and the West African clade, the latter of
which has been identified as the predominant clade in the current
multi-country outbreak.
"The monkeypox controls are the most recent addition to our
expanding portfolio of synthetic controls and reference standards
that empower our customers to develop research and diagnostic tests
to improve global health. They also complement our growing suite of
NGS applications for viral diseases, including the Twist Pan-Viral
Panel, which was used by researchers to characterize the monkeypox
pathogen in a previous outbreak and highlighted in The Lancet2,”
said Emily M. Leproust, Ph.D., CEO and co-founder of Twist
Bioscience. “As new and existing pathogens emerge as public health
concerns, we will continue to rapidly develop tools to enable
cutting edge research that improve global health outcomes.”
The monkeypox synthetic DNA controls are designed based on
specific monkeypox clades, cover over 80% of the full viral genome
and are sequence-verified using NGS and ddPCR. Each control is made
up of 1.8kb of overlapping fragments that tile the genome.
Customers purchasing synthetic controls are subject to Twist’s
leading biosecurity and customer screening protocols and applicable
laws and regulations. An export license will be required for
international customers.
Twist provides a suite of research tools and NGS products,
including custom controls and reference standards for monkeypox,
respiratory diseases including coronaviruses, influenza viruses,
paramyxoviruses and enteroviruses as well as liquid biopsy and
cancers. Twist also offers the Twist Pan-Viral Panel, which
contains over 600,000 probes for the targeted enrichment of over
1,000 viral human pathogens, including those that cause monkeypox,
Zika virus and other diseases. In a study published in The Lancet
Infectious Diseases in 2018, researchers used the Twist Pan-Viral
Panel to screen blood samples for viral content to analyze the
genetic makeup and origin of a monkeypox virus outbreak in
Nigeria.
To learn more about the Twist monkeypox virus synthetic DNA
controls, visit:
https://www.twistbioscience.com/MonkeypoxControls.
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic
biology and genomics company that has developed a disruptive DNA
synthesis platform to industrialize the engineering of biology. The
core of the platform is a proprietary technology that pioneers a
new method of manufacturing synthetic DNA by “writing” DNA on a
silicon chip. Twist is leveraging its unique technology to
manufacture a broad range of synthetic DNA-based products,
including synthetic genes, tools for next-generation sequencing
(NGS) preparation, and antibody libraries for drug discovery and
development. Twist is also pursuing longer-term opportunities in
digital data storage in DNA and biologics drug discovery. Twist
makes products for use across many industries including healthcare,
industrial chemicals, agriculture and academic research.
Follow us on Twitter | Facebook | LinkedIn | YouTube
Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements. All
statements other than statements of historical facts contained
herein, including without limitation Twist’s ability to deliver
synthetic controls for monkeypox to its customers, are
forward-looking statements reflecting the current beliefs and
expectations of management made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements involve known and unknown risks,
uncertainties, and other important factors that may cause Twist
Bioscience’s actual results, performance, or achievements to be
materially different from any future results, performance, or
achievements expressed or implied by the forward-looking
statements. For a description of the risks and uncertainties that
could cause actual results to differ from those expressed in these
forward-looking statements, as well as risks relating to Twist
Bioscience’s business in general, see Twist Bioscience’s risk
factors set forth in Twist Bioscience’s Quarterly Report on Form
10-Q filed with the Securities and Exchange Commission on May 6,
2022 and subsequent filings with the SEC. Any forward-looking
statements contained in this press release speak only as of the
date hereof, and Twist Bioscience specifically disclaims any
obligation to update any forward-looking statement, whether as a
result of new information, future events or otherwise.
1 Due to the urgent need to make the monkeypox synthetic
controls available to customers, they are not yet ISO
certified.
2 Faye, O., Pratt, C.B., Faye, M., Fall, G., Chitty, J.A., et
al., 2018. Genomic characterisation of human monkeypox virus in
Nigeria. The Lancet Infectious Diseases 18, 246.
https://doi.org/10.1016/S1473-3099(18)30043-4
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220714005279/en/
For Twist Bioscience: Angela Bitting SVP, Corporate
Affairs 925- 202-6211 abitting@twistbioscience.com
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Jun 2024 to Jul 2024
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Jul 2023 to Jul 2024